' 
![]()
SCIENTIFIC SCORE
Possibly Effective
Based on 36 Researches
7.4
USERS' SCORE
Good
Based on 2 Reviews
8.6
Supplement Facts
Serving Size: 2 Soft Gels
Amount Per Serving
%DV
Calories
20
Total Fat
2 g
3%
Saturated Fat
0 g
0%
Trans Fat
0 g
†
Vitamin D3 (cholecalciferol)
25 mcg (1000 IU)
125%
Total Omega-3s♦
1280 mg
†
EPA (Eicosapentaenoic Acid)
650 mg
†
DHA (Docosahexaenoic Acid)
450 mg
†
Top Medical Research Studies
9.5
Eicosapentaenoic acid helps migraines
A 12-week randomized double-blind clinical trial of eicosapentaenoic acid intervention in episodic migraine.
Directly addresses EPA efficacy
We conducted a thorough investigation into how eicosapentaenoic acid (EPA) can impact episodic migraines. In a carefully designed study, we gathered 70 participants who experienced these migraines and divided them into two groups. One group received a high dose of EPA, while the other was given a placebo. This approach ensured that we could see the true effects of EPA without bias.
After 12 weeks, the results were compelling. We noticed that those taking EPA had significantly fewer migraine days compared to the placebo group. In fact, participants on EPA reported an average reduction of 4.4 days per month, while those on the placebo had barely any change. The EPA group also experienced less need for acute headache medication and marked improvements in headache severity, disability, anxiety, depression, and overall quality of life.
Perhaps most striking was how particularly beneficial EPA seemed to be for female participants. Overall, the study demonstrated that high-dose EPA not only helped reduce the frequency and severity of migraines but also positively influenced the psychological aspects of living with migraines.
This suggests that incorporating EPA into migraine management could be a valuable option for those suffering from episodic migraines, especially as there were no major adverse effects reported.
After 12 weeks, the results were compelling. We noticed that those taking EPA had significantly fewer migraine days compared to the placebo group. In fact, participants on EPA reported an average reduction of 4.4 days per month, while those on the placebo had barely any change. The EPA group also experienced less need for acute headache medication and marked improvements in headache severity, disability, anxiety, depression, and overall quality of life.
Perhaps most striking was how particularly beneficial EPA seemed to be for female participants. Overall, the study demonstrated that high-dose EPA not only helped reduce the frequency and severity of migraines but also positively influenced the psychological aspects of living with migraines.
This suggests that incorporating EPA into migraine management could be a valuable option for those suffering from episodic migraines, especially as there were no major adverse effects reported.
Read More
9.5
Omega-3s effectively reduce migraines
High Dosage Omega-3 Fatty Acids Outperform Existing Pharmacological Options for Migraine Prophylaxis: A Network Meta-Analysis.
Directly addresses migraine treatment
We explored the potential of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) as effective treatments for preventing migraines. In a comprehensive analysis of 40 randomized controlled trials involving over 6,600 participants, we compared high doses of these omega-3 fatty acids with other commonly prescribed migraine medications.
Our findings revealed that higher dosages of EPA/DHA resulted in significant decreases in both the frequency and severity of migraines compared to a placebo. Specifically, we observed a notable standardized mean difference in migraine frequency and severity, indicating these omega-3s might be a more effective option than current medications.
Moreover, the acceptance rates of this treatment were promising, suggesting that individuals found it easier to tolerate compared to traditional migraine drugs. This evidence supports the idea that high dosage EPA/DHA could be a leading choice for migraine prevention, potentially offering a safer and more effective alternative for many patients.
Our findings revealed that higher dosages of EPA/DHA resulted in significant decreases in both the frequency and severity of migraines compared to a placebo. Specifically, we observed a notable standardized mean difference in migraine frequency and severity, indicating these omega-3s might be a more effective option than current medications.
Moreover, the acceptance rates of this treatment were promising, suggesting that individuals found it easier to tolerate compared to traditional migraine drugs. This evidence supports the idea that high dosage EPA/DHA could be a leading choice for migraine prevention, potentially offering a safer and more effective alternative for many patients.
Read More
9
Vitamin D3 improves migraine symptoms
Vitamin D3 might improve headache characteristics and protect against inflammation in migraine: a randomized clinical trial.
High relevance to migraine treatment
We explored the potential benefits of vitamin D3 supplementation for people suffering from migraines. In a carefully designed study, 80 individuals with episodic migraines participated in a 12-week trial where they were randomly assigned to receive either 2000 IU (50 μg) of vitamin D3 daily or a placebo.
Throughout the study, we closely monitored headache characteristics using diaries and measured various serum inflammatory markers before and after the trial. Our findings showed that those taking vitamin D3 experienced significant improvements. They reported fewer headache days each month, shorter headache durations, and less severe pain overall when compared to the placebo group.
Interestingly, while the levels of some inflammatory markers didn't change much, we did notice a striking reduction in a certain enzyme linked to inflammation in the vitamin D3 group. Additionally, there was a trend toward lower levels of another inflammation marker, suggesting that vitamin D3 might offer a protective effect against neuro-inflammation in migraine sufferers.
In essence, our study indicates that vitamin D3 could be a promising supplemental treatment to help improve the quality of life for those battling episodic migraines.
Throughout the study, we closely monitored headache characteristics using diaries and measured various serum inflammatory markers before and after the trial. Our findings showed that those taking vitamin D3 experienced significant improvements. They reported fewer headache days each month, shorter headache durations, and less severe pain overall when compared to the placebo group.
Interestingly, while the levels of some inflammatory markers didn't change much, we did notice a striking reduction in a certain enzyme linked to inflammation in the vitamin D3 group. Additionally, there was a trend toward lower levels of another inflammation marker, suggesting that vitamin D3 might offer a protective effect against neuro-inflammation in migraine sufferers.
In essence, our study indicates that vitamin D3 could be a promising supplemental treatment to help improve the quality of life for those battling episodic migraines.
Read More
Most Useful Reviews
8.8
Dissipating migraines
These are easy to swallow with no fishy burps, unlike other omega 3 supplements. I'm using them to increase my EPA and DHA intake, as I don't particularly like fish. I've noticed that my migraines have begun to dissipate. The dietitians I work with highly recommend this product for supplementation when natural sources are unavailable.
Read More
8.8
Reduced migraines
The best omega; I take it all the time. It’s excellent for women. Since I started, the frequency of my migraines has decreased, and my skin has improved.
Read More
Medical Researches
SCIENTIFIC SCORE
Possibly Effective
Based on 36 Researches
7.4
9.5
Effective migraine prevention strategy
Simvastatin and vitamin D for migraine prevention: A randomized, controlled trial.
Combines vitamin D with treatment
We conducted a thorough investigation into the effectiveness of simvastatin paired with vitamin D3 for preventing migraines in adults with episodic migraine. Our study was a well-structured randomized, double-blind, placebo-controlled trial involving 57 participants over a span of 24 weeks.
Participants were divided into two groups: one receiving simvastatin and vitamin D3, while the other received placebos. Throughout the trial, we observed that those taking the combination of simvastatin and vitamin D3 experienced a significant reduction in the number of migraine days when compared to those on placebos. Specifically, during the first 12 weeks, participants on the active regimen reported a decrease of 8.0 migraine days, whereas those on placebos noted an increase of 1.0 migraine days.
By the end of the 24-week period, an impressive 29% of participants taking the medication reported a 50% or more reduction in their migraine days. In contrast, only 3% of those taking the placebo experienced similar relief. Interestingly, we found that the occurrence of adverse events was similar in both groups, indicating that the combination therapy was generally well-tolerated.
Our findings showcase the potential benefits of using simvastatin alongside vitamin D3 as an effective strategy for managing migraines, while also addressing some underlying health risks associated with migraines, such as vascular issues.
Participants were divided into two groups: one receiving simvastatin and vitamin D3, while the other received placebos. Throughout the trial, we observed that those taking the combination of simvastatin and vitamin D3 experienced a significant reduction in the number of migraine days when compared to those on placebos. Specifically, during the first 12 weeks, participants on the active regimen reported a decrease of 8.0 migraine days, whereas those on placebos noted an increase of 1.0 migraine days.
By the end of the 24-week period, an impressive 29% of participants taking the medication reported a 50% or more reduction in their migraine days. In contrast, only 3% of those taking the placebo experienced similar relief. Interestingly, we found that the occurrence of adverse events was similar in both groups, indicating that the combination therapy was generally well-tolerated.
Our findings showcase the potential benefits of using simvastatin alongside vitamin D3 as an effective strategy for managing migraines, while also addressing some underlying health risks associated with migraines, such as vascular issues.
Read More
9.5
Eicosapentaenoic acid helps migraines
A 12-week randomized double-blind clinical trial of eicosapentaenoic acid intervention in episodic migraine.
Directly addresses EPA efficacy
We conducted a thorough investigation into how eicosapentaenoic acid (EPA) can impact episodic migraines. In a carefully designed study, we gathered 70 participants who experienced these migraines and divided them into two groups. One group received a high dose of EPA, while the other was given a placebo. This approach ensured that we could see the true effects of EPA without bias.
After 12 weeks, the results were compelling. We noticed that those taking EPA had significantly fewer migraine days compared to the placebo group. In fact, participants on EPA reported an average reduction of 4.4 days per month, while those on the placebo had barely any change. The EPA group also experienced less need for acute headache medication and marked improvements in headache severity, disability, anxiety, depression, and overall quality of life.
Perhaps most striking was how particularly beneficial EPA seemed to be for female participants. Overall, the study demonstrated that high-dose EPA not only helped reduce the frequency and severity of migraines but also positively influenced the psychological aspects of living with migraines.
This suggests that incorporating EPA into migraine management could be a valuable option for those suffering from episodic migraines, especially as there were no major adverse effects reported.
After 12 weeks, the results were compelling. We noticed that those taking EPA had significantly fewer migraine days compared to the placebo group. In fact, participants on EPA reported an average reduction of 4.4 days per month, while those on the placebo had barely any change. The EPA group also experienced less need for acute headache medication and marked improvements in headache severity, disability, anxiety, depression, and overall quality of life.
Perhaps most striking was how particularly beneficial EPA seemed to be for female participants. Overall, the study demonstrated that high-dose EPA not only helped reduce the frequency and severity of migraines but also positively influenced the psychological aspects of living with migraines.
This suggests that incorporating EPA into migraine management could be a valuable option for those suffering from episodic migraines, especially as there were no major adverse effects reported.
Read More
9.5
Omega-3s effectively reduce migraines
High Dosage Omega-3 Fatty Acids Outperform Existing Pharmacological Options for Migraine Prophylaxis: A Network Meta-Analysis.
Directly addresses migraine treatment
We explored the potential of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) as effective treatments for preventing migraines. In a comprehensive analysis of 40 randomized controlled trials involving over 6,600 participants, we compared high doses of these omega-3 fatty acids with other commonly prescribed migraine medications.
Our findings revealed that higher dosages of EPA/DHA resulted in significant decreases in both the frequency and severity of migraines compared to a placebo. Specifically, we observed a notable standardized mean difference in migraine frequency and severity, indicating these omega-3s might be a more effective option than current medications.
Moreover, the acceptance rates of this treatment were promising, suggesting that individuals found it easier to tolerate compared to traditional migraine drugs. This evidence supports the idea that high dosage EPA/DHA could be a leading choice for migraine prevention, potentially offering a safer and more effective alternative for many patients.
Our findings revealed that higher dosages of EPA/DHA resulted in significant decreases in both the frequency and severity of migraines compared to a placebo. Specifically, we observed a notable standardized mean difference in migraine frequency and severity, indicating these omega-3s might be a more effective option than current medications.
Moreover, the acceptance rates of this treatment were promising, suggesting that individuals found it easier to tolerate compared to traditional migraine drugs. This evidence supports the idea that high dosage EPA/DHA could be a leading choice for migraine prevention, potentially offering a safer and more effective alternative for many patients.
Read More
9.5
Omega-3s effective for migraine
High Dosage Omega-3 Fatty Acids Outperform Existing Pharmacological Options for Migraine Prophylaxis: A Network Meta-Analysis.
Overall study shows positive results
We dug into how docosahexaenoic acid (DHA), along with eicosapentaenoic acid (EPA), can help with migraine management. Through a comprehensive analysis of 40 randomized controlled trials involving over 6,600 participants, we compared various treatments for migraine prevention. Our focus was on the effectiveness and acceptability of high doses of DHA and EPA against other standard medications.
What we found was quite intriguing. Supplementing with high doses of EPA and DHA significantly reduced the frequency of migraines as compared to placebo treatments. In fact, our analysis revealed a notable decrease in migraine severity as well. Not only that, but those using high-dose omega-3s reported favorable experiences with treatment, showcasing a high level of acceptability.
This compelling evidence suggests that high doses of DHA and EPA can serve as a premier option for preventing migraines. Their effectiveness and tolerability make them an attractive choice for those seeking relief. The potential of omega-3 supplementation in this context opens new avenues for migraine management that are worth exploring further.
What we found was quite intriguing. Supplementing with high doses of EPA and DHA significantly reduced the frequency of migraines as compared to placebo treatments. In fact, our analysis revealed a notable decrease in migraine severity as well. Not only that, but those using high-dose omega-3s reported favorable experiences with treatment, showcasing a high level of acceptability.
This compelling evidence suggests that high doses of DHA and EPA can serve as a premier option for preventing migraines. Their effectiveness and tolerability make them an attractive choice for those seeking relief. The potential of omega-3 supplementation in this context opens new avenues for migraine management that are worth exploring further.
Read More
9
Pediatric migraine relief with vitamin D
The Impact of Vitamin D Supplementation to Topiramate Therapy on Pediatric Migraine Prophylaxis.
Combination therapy raises questions
We conducted a study to evaluate how vitamin D supplementation affects migraine relief in children aged 5 to 14 who are also taking topiramate, a common migraine medication. Our trial involved a double-blind design, where participants were randomly assigned to either receive vitamin D or a placebo alongside their topiramate treatment for four months.
The results were promising. Children who took vitamin D showed a significant decrease in the monthly frequency of their headaches and a lowered disability score related to migraines compared to those who received the placebo. Notably, about 76% of the kids in the vitamin D group reported a good response to the treatment, while only 53.5% in the placebo group did.
We also found that the side effects of both treatments were minimal and similar, indicating that vitamin D supplementation is generally well-tolerated. These findings suggest that adding vitamin D to topiramate can be an effective and safe strategy for managing migraines in young patients.
The results were promising. Children who took vitamin D showed a significant decrease in the monthly frequency of their headaches and a lowered disability score related to migraines compared to those who received the placebo. Notably, about 76% of the kids in the vitamin D group reported a good response to the treatment, while only 53.5% in the placebo group did.
We also found that the side effects of both treatments were minimal and similar, indicating that vitamin D supplementation is generally well-tolerated. These findings suggest that adding vitamin D to topiramate can be an effective and safe strategy for managing migraines in young patients.
Read More
User Reviews
USERS' SCORE
Good
Based on 2 Reviews
8.6
8.8
Reduced migraines
The best omega; I take it all the time. It’s excellent for women. Since I started, the frequency of my migraines has decreased, and my skin has improved.
8.8
Dissipating migraines
These are easy to swallow with no fishy burps, unlike other omega 3 supplements. I'm using them to increase my EPA and DHA intake, as I don't particularly like fish. I've noticed that my migraines have begun to dissipate. The dietitians I work with highly recommend this product for supplementation when natural sources are unavailable.
Read More
